Detail akcie Ironwood Pharma online

Business Summary: Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Ironwood Pharmaceuticals, Inc. revenues increased 8% to $442.7M. Net loss totaled $1B vs. income of $175.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Research and development increase from $39.3M to $98.6M (expense), Selling, general and administrative increase of 25% to $117.1M (expense).